—
The global cancer pain market size accounted for $5.53 Billion in 2018 and is projected to reach $7.54 billion by 2025, registering a CAGR of 4.5% during the forecast period. Cancer Pain Market by Drug Type (Opioids, Non-Opioids, and Nerve Blockers) and Disease Indication (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Blood Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025Increase in incidence of cancer worldwide, surge in healthcare expenditure, and advancements in technology drive the growth of the global cancer pain market
Download PDF Sample: www.alliedmarketresearch.com/request-sample/5123
Based on drug type, the opioids segment contributed the highest market share in 2018, accounting for nearly three-fifths of the total share, and is expected to continue its dominant position throughout the forecast period. Moreover, this segment is expected to grow at the highest CAGR of 5.0% from 2018 to 2025.
This is attributed to rise in adoption of opioids for management of cancer pain and their nature of being the FDA-approved first line drugs for treating moderate or severe chronic cancer pain. The report also analyzes non-opioids and nerve blockers segments.
The report also analyzes colorectal cancer, breast cancer, prostate cancer, blood cancer, and others.
The global cancer pain market is analyzed across various regions such as North America, Europe, Asia-Pacific, and LAMEA. The market across the Asia-pacific region is estimated to manifest the fastest CAGR of 5.4% during the forecast period.
Lung cancer segment to maintain its leadership status during the forecast period
Based on disease indication, the lung cancer segment held the major share in 2018, contributing for nearly one-fourth of the total market share, and is expected to maintain its leadership status during the forecast period. In addition, this segment would grow at the fastest CAGR of 6.1% from 2018 to 2025.
This is a lucrative segment, owing to high prevalence of lung cancer and increase in the usage of cancer pain killers to get relief, upsurge in cigarette smoking population, and availability of advanced diagnostic techniques.
North America to maintain its highest share by 2025
Based on region, North America accounted for the major market share in 2018, accounting for more than two-fifths of the total market share. This region is expected to maintain its highest share during the forecast period.
This is due to rapid increase in prevalence of different types of cancers, advancements in technologies, ease in availability of pain therapeutics, and availability of premiere chemotherapy treatments. On the other hand, Asia-Pacific would register the fastest growth rate with a CAGR of 5.4% from 2018 to 2025, owing to rise in prevalence of cancer in China, Japan, and India, increase in early screening of cancer, and surge in availability of pain therapeutics.
For Enquiry at: www.alliedmarketresearch.com/-enquiry/5123
The global cancer pain market report provides an in-depth analysis of the major market players such as
BioDelivery Sciences International, Inc.
Aoxing Pharmaceutical Company, Inc.
Grnenthal Pharma GmbH & Co. KG
Daiichi Sankyo Co., Ltd.
Insys Therapeutics, Inc.
Hisamitsu Pharmaceutical Co., Inc.
Orexo AB
Mundipharma International Limited
Teva Pharmaceutical Industries Limited
Pfizer Inc.
Read More: https://www.alliedmarketresearch.com/press-release/cancer-pain-market.html
Contact Info:
Name: David Correa
Email: Send Email
Organization: Allied Market Research
Website: https://www.alliedmarketresearch.com/
Release ID: 89031875
Google
RSS